Lanean...
Inflammatory bowel disease: towards a personalized medicine
The management of inflammatory bowel disease (IBD) has been transformed over the last two decades by the arrival of tumor necrosis factor (TNF) antagonist agents. Recently, alternative drugs have been approved, directed at leukocyte-trafficking molecules (vedolizumab) or other inflammatory cytokines...
Gorde:
| Argitaratua izan da: | Therap Adv Gastroenterol |
|---|---|
| Egile Nagusiak: | , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
SAGE Publications
2018
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5784543/ https://ncbi.nlm.nih.gov/pubmed/29383027 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756283X17745029 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|